Consonance Capital Management’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Consonance Capital Management’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1,143,315	Closed	-$37.6M	–	30
2014 Q2	$37.6M	Buy	1,143,315 +712,426	+165%	+$24.4M	5.59%	6
2014 Q1	$15.9M	Sell	430,889 -821,425	-66%	-$30.1M	2.36%	16
2013 Q4	$48.1M	Buy	1,252,314 +250,800	+25%	+$7.92M	7.88%	2
2013 Q3	$27.4M	Buy	+1,001,514	New	+$23.7M	6.86%	4

Other funds holding WX

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Consonance Capital Management's WX Position: Q3 2014 in Review

Consonance Capital Management sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q3 2014, closing a stake of 1,143,315 shares — an estimated $37.6M sold.

Consonance Capital Management first reported a position in WX in Q3 2013 and held it in 4 quarters. The position peaked at $48.1M in Q4 2013. 157 funds tracked by Wall St. Rank hold WX as of Q3 2014.

Consonance Capital Management reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q3 2014 after selling out during the quarter.
Consonance Capital Management sold 1,143,315 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q3 2014, an estimated $37.6M.
Consonance Capital Management first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 4 quarters.
Consonance Capital Management's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $48.1M in Q4 2013.
157 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q3 2014.

Based on Consonance Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.